Skip to search formSkip to main contentSkip to account menu

Oral Azacitidine

An orally bioavailable formulation of azacitidine, a pyrimidine nucleoside analogue of cytidine, with antineoplastic activity. Upon oral… 
National Institutes of Health

Related topics

Related topics

1 relation

Narrower (1)

CC-486

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer
Purpose CC-486 is an oral formulation of azacitidine that allows for extended dosing schedules to prolong azacitidine exposure to… 
2017
2017
A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients (pts) with metastatic melanoma (MM).
9560 Background: Immune checkpoint blockade (ICB) have improved survival for many pts with MM, offering durable responses in up… 
2016
2016
CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies
Background: Injectable HMAs (azacitidine [AZA], decitabine) are the standard of care in higher-risk myelodysplastic syndromes (HR… 
2015
2015
CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)
Background: When administered subcutaneously (SC), the epigenetic modifier, azacitidine (AZA) is shown to improve overall… 
2014
2014
Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies
Parenteral azacitidine improves overall survival in higher‐risk myelodysplastic syndromes. An oral azacitidine formulation would… 
2012
2012
Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes
Abstract 424 Background: Azacitidine for injection has been shown to prolong overall survival in patients (pts) with higher-risk… 
2012
2012
Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule
Abstract 1337 Background: Oral azacitidine (CC-486) is bioavailable, biologically and clinically active, and well tolerated in… 
2010
2010
Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study
Abstract 603 Parenteral azacitidine (AZA) is approved for administration on days 1–7 of a 28-day treatment schedule. Based on the… 
2009
2009
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous…
Abstract 117 Background: Parenteral azacitidine significantly improves overall survival of subjects with higher-risk MDS and WHO… 
2008
2008
A phase I, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in subjects with myelodysplastic syndromes (MDS) or acute myelogenous…
7091 Background: Azacitidine, a cytidine analog, through its effects on DNA metabolism, gene expression, and cell differentiation… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)